erus BioSciences(CHRS) - 2024 Q2 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total sales increased by 10% year-over-year in Q2 2024, rising from $59 million to $65 million, excluding the divested CIMERLI [5][9] - Q2 2024 net loss was $12.99 million, or $0.11 per diluted share, compared to a net loss of $42.99 million, or $0.49 per diluted share for the same period in 2023 [30] - Cash, cash equivalents, and investments in marketable securities were $159.2 million as of June 30, 2024, compared to $117.7 million at year-end [30] Business Line Data and Key Metrics Changes - UDENYCA net revenue was $50.9 million in Q2 2024, a 19% increase quarter-over-quarter and a 60% increase over Q2 2023 [9] - LOQTORZI net revenue nearly doubled to $3.8 million in Q2 2024, compared to $2 million in Q1 2024 [9] - UDENYCA franchise demand grew by 25% in Q2 2024, with all three product presentations showing growth [15] Market Data and Key Metrics Changes - LOQTORZI is now accessible in all 33 NCCN institutions, indicating strong market penetration [38] - The estimated market for LOQTORZI in the nasopharyngeal carcinoma (NPC) segment is valued at $150 million to $200 million [15] - Approximately 60% of NPC patients in the U.S. are treated in academic NCCN settings, while 40% are treated in community settings [51] Company Strategy and Development Direction - The company is focusing on oncology, streamlining operations and portfolio to enhance growth [5] - The strategic approach includes advancing a pipeline of innovative immuno-oncology drug candidates and establishing partnerships for development [18][25] - The company aims to drive top-line growth, control operating expenses, and improve capital structure [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the execution of their strategy and the potential for LOQTORZI to achieve a dominant market share in the NPC market [15][32] - The company is optimistic about the continued growth of UDENYCA, driven by innovative device presentations and broad payer coverage [15][41] - Management highlighted the importance of engaging community oncologists to drive new patient acquisition for LOQTORZI [52] Other Important Information - The company ended Q2 2024 with $159 million on the balance sheet, indicating strong cash management [7] - The company has reiterated its expected range of combined 2024 R&D and SG&A expenses of $250 million to $265 million [31] Q&A Session Summary Question: Can you provide insights on the LOQTORZI launch in NPC? - The patient mix includes both newly diagnosed patients and those switching from off-label PD-1 treatments, with nearly 100% payer coverage achieved [34][35] Question: What is driving UDENYCA's unit growth? - The growth is attributed to the commercial launch of the on-body device, broad payer coverage, and stable average selling price [40][41] Question: How does the company plan to penetrate the broader community for the NPC market? - The company plans to engage community oncologists to ensure they are prepared to treat LOQTORZI eligible patients [52]